Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI)

Cardiology Journal

Volumn 20, Issue 2, 2013, Pages 125-133

  Stepińska, Janina ^a   Czerwińska, Katarzyna ^a   Witkowski, Adam ^a   Dabrowski, Maciej ^a   Chmielak, Zbigniew ^a   Kuśmierski, Krzysztof ^a   Hryniewiecki, Tomasz ^a   Demkow, Marcin ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Antithrombotic therapy; Aortic stenosis; Bleeding complications; Transcatheter aortic valve implantation (TAVI)

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL;

ADULT; AGED; ARTICLE; BIOPROSTHESIS; BLEEDING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FISHER EXACT TEST; GENDER; GUSTO RATING SCALE; HASBLED SCALE; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROGNOSIS; RANK SUM TEST; RATING SCALE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TIMI RATING SCALE; TRANSCATHETER AORTIC VALVE IMPLANTATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; ANTICOAGULANTS; AORTIC VALVE STENOSIS; BLOOD TRANSFUSION; CARDIAC CATHETERIZATION; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; POLAND; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84878501125     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0024     Document Type: Article

References (36)

1. Vahanian A, Baoumgartner H, Bax J et al. Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J, 2007; 28: 230-268.
2. Vahanian A, Alfieri O, Al-Attar N et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2008; 29: 1463-1470.
3. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Eur Heart J, 2007; 28: 1598-660.
4. Moscucci M, Fox KA, Cannon CP et al. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J, 2003; 24: 1815-1823.
5. Mehran R, Pocock SJ, Stone GW et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur Heart J, 2009; 30: 1457-1466.
6. Shishehbor MH, Madhwal S, Rajagopal V et al. Impact of blood transfusion on shortand long-term mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol Cardiovasc Interv, 2009; 2: 46-53.
7. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J, 2005; 149: 217-226.
8. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med, 1993; 329: 673-682.
9. Leon M, Piazza N, Nikolsky E et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: A consensus report from the Valve Academic Research Consortium. Eur Heart J, 2011; 32: 205-217.
10. Rosenhek R, Iung B, Tornos P et al. ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. doi:10.1093/eurheartj/ehr061. http://eurheartj.oxfordjournals.org/content/early//2011/03/14/eurheartj.ehr061.full.pdf+html (15 March 2011).
11. Osswald BR, Gegouskov V, Badowski-Zyla D et al. Overestimation of aortic valve replacement risk by EuroSCORE: Implications for percutaneous valve replacement. Eur Heart J, 2009; 30: 74-80.
12. Nuis RJ, Piazza N, Van Mieghem N, Otten AM et al. In-Hospital Complications After Transcatheter Aortic Valve Implantation Revisited According to the Valve Academic Research Consortium Definitions. Catheter Cardiovasc Interv. 2011;1: 457-467.
13. Thomas M, Schymik G, Walther T et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation, 2010; 122: 62-69.
14. Gurvitch R, Toggweiler S, Willson AB et al. Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines. EuroIntervention, 2011; 7: 41-48.
15. Moreno R, Calvo L, Salinas P et al. Causes-peri-operative-mortality-aftertranscatheter-aortic-valve-implantation-pooled-analys. J Invasive Cardiol, 2011; 23: 180-184.
16. Leon MB, Smith CR, Mack MJ et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med, 2010; 363: 1597-1607.
17. Smith CR, Leon MB, Mack MJ et al. Transcatheter versus Surgical Aortic Valve Replacement in High-Risk Patients. N Engl J Med, 2011; 364: 2187-2198.
18. Ducrocq G, Francis F, Serfaty JM et al. Vascular complications of trans femoral aortic valve implantation with the Edwards SAPIEN prosthesis: Incidence and impact on outcome. EuroIntervention, 2010; 5: 666-672.
19. Karjalainen PP, Vikman S, Niemela M et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J, 2008; 29: 1001-1010.
20. Nguyen MC, Lim YL, Walton A et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J, 2007; 28: 1717-1722.
21. Manzano-Fernández S, Pastor FJ, Marin F et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest, 2008; 134: 559-567.
22. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke, 2004; 35: 2362-2367.
23. Dunning J, Versteeg M, Fabbr A et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardio-Thorac Surg, 2008; 34: 73-79.
24. Fitchett D, Eikelboom J, Fremes S et al. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Can J Cardiol, 2009; 25: 683-689.
25. Ebrahimi R, Dyke C, Mehran R et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 2009; 53: 1965-1972.
26. Shahbudin H. Rahimtoola. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol, 2003; 41: 893-904.
27. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The Pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004; 126: 204-233.
28. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Heart Survey. Chest, 2010; 138: 1093-1100.
29. Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol, 2010; 55: 2556-2566.
30. Cladellas M, Bruguera J, Comin J et al. Is pre-operative anaemia a risk marker for in-hospital mortality and morbidity after valve replacement? Eur Heart J, 2006; 27: 1093-1099.
31. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation, 2003; 107: 223-225.
32. Nikolsky E, Mehran R, Dangas G et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing precutaneous coronary intervention via the femoral approach. Eur Heart J, 2007; 28:1936-1945.
33. Halliday BP, Dworakowski R, Brickham B et al. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol, 2012; 109: 724-728.
34. Van Mieghem NM, Nuis RJ, Tzikas A et al. Prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation. Eurointervention, 2011; 7: 184-191.
35. Rao S, O'Grady K, Pieper KS et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol, 2006; 47: 809-816.
36. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost, 2010; 8: 202-204.